| Oct 29 |
GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint
|
| Jul 25 |
GlycoMimetics to cut workforce by about 80% in corporate restructuring plan
|
| Jul 25 |
GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan
|
| Jun 26 |
Senior VP & Chief Medical Officer of GlycoMimetics Edwin Rock Buys 81% More Shares
|
| Jun 21 |
$1M Bet On This Penny Stock? Check Out These 4 Stocks Under $2 Insiders Are Aggressively Buying
|
| Jun 4 |
GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
|
| May 29 |
GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024
|
| May 28 |
Pipeline Moves: Phase III AML trial fails to meet primary endpoint
|
